Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2014 March;16(1) > Esperienze Dermatologiche 2014 March;16(1):13-5





A Journal on Dermatology

Journal of Istituto Dermatologico San Gallicano
Official Journal of the Associazione Dermatologi Ospedalieri Italiani - A.D.O.I.
Indexed/Abstracted in: EMBASE, Scopus



Esperienze Dermatologiche 2014 March;16(1):13-5

language: Italian

Psoriasis induced by certolizumab: a report of two cases

Colasanti P. 1, Tirri E. 2, Cordedda M. 1, Maione F. 1, Spanò G. 1, Zanchini R. 1, Mozzillo R. 1

1 Presidio Ospedaliero S. Gennaro, ASL Napoli 1 Centro, UOSD di Dermatologia, Napoli, Italia;
2 Presidio Ospedaliero S. Giovanni Bosco, Napoli ASL Napoli 1 Centro, UOSD di Reumatologia, Napoli, Italia


The occurrence of psoriasis in patients treated with tumor necrosis factor-alpha (TNF-α) is defined “paradoxical effect” and is characterized by the development of de novo psoriasis induced by the use of a drug which is normally utilized to treat skin disease itself. The authors describe two cases of de novo psoriasis in female patients affected by rheumatoid arthritis treated with certolizumab pegol (Cimzia®), a recombinant humanized antibody Fab fragment antibody directed against TNF-α conjugated with propylene glycol. In both cases personal or familiar history was negative for psoriasis. It is important for clinicians to be aware of this possible drug effect, especially considering the increasingly widespread use of these drugs.

top of page

Publication History

Cite this article as

Corresponding author e-mail